LeMaitre Vascular (NASDAQ:LMAT) Releases FY 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.930-3.080 for the period, compared to the consensus estimate of 2.900. The company issued revenue guidance of $277.0 million-$283.0 million, compared to the consensus revenue estimate of $279.5 million. LeMaitre Vascular also updated its Q2 2026 guidance to 0.790-0.840 EPS.

LeMaitre Vascular Stock Down 2.1%

Shares of NASDAQ:LMAT traded down $2.31 during trading on Thursday, hitting $107.91. The stock had a trading volume of 363,632 shares, compared to its average volume of 182,455. LeMaitre Vascular has a 12 month low of $78.35 and a 12 month high of $118.01. The company has a market capitalization of $2.47 billion, a PE ratio of 39.82, a PEG ratio of 3.06 and a beta of 0.60. The firm’s fifty day moving average is $110.00 and its 200 day moving average is $94.48. The company has a quick ratio of 10.95, a current ratio of 14.32 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. During the same quarter in the prior year, the company earned $0.48 EPS. The business’s revenue was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Analysts anticipate that LeMaitre Vascular will post 3 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be given a $0.25 dividend. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s dividend payout ratio is currently 36.90%.

Wall Street Analyst Weigh In

LMAT has been the subject of several research reports. Roth Mkm reissued a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Barrington Research raised their price objective on LeMaitre Vascular from $105.00 to $120.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Wells Fargo & Company raised their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of LeMaitre Vascular stock in a transaction on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the sale, the insider owned 6,677 shares of the company’s stock, valued at approximately $736,406.33. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO George W. Lemaitre sold 55,930 shares of LeMaitre Vascular stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total value of $6,029,813.30. Following the completion of the sale, the chief executive officer directly owned 1,476,500 shares of the company’s stock, valued at approximately $159,181,465. The trade was a 3.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 215,438 shares of company stock valued at $23,062,911. Corporate insiders own 7.40% of the company’s stock.

Key Stories Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Several firms raised price targets and issued upbeat notes, supporting upside. Barrington raised its target to $120 and reiterates an outperform view. Barrington Research Raises Target
• Positive Sentiment: Citizens JMP lifted its target to $127 and kept a market?outperform stance, the most bullish target among recent updates. Citizens JMP Raises Target
• Positive Sentiment: Zacks upgraded LMAT to a Rank #2 (Buy) and published a bullish piece highlighting growth characteristics that could attract investors. LeMaitre (LMAT) Upgraded to Buy: Here’s Why
• Positive Sentiment: Company Q1 results beat EPS estimates modestly and management gave FY?2026 EPS guidance of $2.93–$3.08 (Q2 guidance $0.79–$0.84), supporting higher analyst valuations around ~$118 consensus. Strong margins and revenue growth underpinned the upbeat notes. US$118 – That’s What Analysts Think…
• Positive Sentiment: LeMaitre declared a quarterly dividend ($0.25/share), modestly supportive for income-minded investors and signaling confidence in cash flow. (Ex?dividend May 21.)
• Neutral Sentiment: Management will present at the Bank of America Healthcare Conference on May 13 — an opportunity for investor Q&A but not a guaranteed catalyst. LeMaitre to Present at the Bank of America Healthcare Conference
• Neutral Sentiment: Wells Fargo raised its target to $104 but kept an Equal Weight rating — the move is less bullish than other shops and reflects mixed analyst views on near?term upside. Wells Fargo Target Raise
• Neutral Sentiment: The Q1 earnings call transcript and deep?dive coverage outline drivers — Artegraft expansion and pricing helped margins — but also note cautious market reaction; useful reading for investors deciding whether margins and growth justify the higher multiples. Q1 2026 Earnings Call Transcript LMAT Q1 deep dive…
• Negative Sentiment: Despite the positive notes, some coverage and market participants remain cautious about sustainability of margin gains and valuation (mixed analyst ratings persist), which likely contributed to the share pullback today.

Institutional Trading of LeMaitre Vascular

Institutional investors and hedge funds have recently modified their holdings of the business. Numerai GP LLC bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth $573,000. Canada Pension Plan Investment Board increased its holdings in shares of LeMaitre Vascular by 384.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 6,300 shares of the medical instruments supplier’s stock worth $523,000 after purchasing an additional 5,000 shares in the last quarter. Horizon Investments LLC bought a new stake in shares of LeMaitre Vascular in the 3rd quarter worth $520,000. EntryPoint Capital LLC bought a new stake in shares of LeMaitre Vascular in the 4th quarter worth $449,000. Finally, Mercer Global Advisors Inc. ADV boosted its stake in shares of LeMaitre Vascular by 11.5% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 3,606 shares of the medical instruments supplier’s stock worth $292,000 after buying an additional 371 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.